Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors

NCT ID NCT03856658

Ongoing Disease control Sponsor: Corewell Health West Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether delivering a chemotherapy drug called floxuridine directly to the liver through a surgically placed pump can better control tumors that have spread from pancreatic cancer. Participants also receive standard chemotherapy. The goal is to see if this combination can slow or stop liver tumor growth and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: floxuridine delivered via a hepatic artery infusion pump
What this could lead to: If successful, this approach could improve control of liver metastases and extend survival for people with pancreatic cancer that has spread to the liver.
What could go wrong: This is a small, early-phase study, so results may not apply broadly. The treatment involves surgery and carries risks such as infection, liver damage, or complications from the pump.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER METASTASES PANCREATIC ADENOCARCINOMA

Contacts and locations

Show contact details

Locations

Corewell Health West

Grand Rapids, Michigan, 49503, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.